Narayana Hrudayalaya Q2 FY27 Earnings Call: India Margin Hits 26.8%, Insurance Losses Narrow To Rs. 20 Crore (NH)

Volume-Led Quarter With Operating Leverage in India

• IP volumes +4% YoY, OP footfall +12% YoY — India business margin printed at 26.8% in Q2 FY 2026-2027 (analyst cited ~25%), aided by doctors/nursing costs down 1.8% via operating leverage; growth came from high-end procedures and higher robotics use with only moderate price increases.
• IP footfalls grew 6% QoQ and almost 4% YoY — Group CFO Sandhya Jayaraman corrected the analyst's "flat at ~60,000" framing, with Vice Chairman Viren Shetty noting this came with no bed additions.
• ARPOB increased from 17.5 million to 19.5 million in FY 2026-2027 — per Group COO; the analyst flagged NH ARPOB of 55,000 vs 70,000 at larger peers and asked whether structural convergence could add ~200bps of margin at peak (period unspecified); management will continue a balanced volume-plus-realization strategy.
• Occupancy has hovered at 60-65% — (traditionally calculated on midnight beds) over the past several quarters through Q2 FY 2026-2027; management does not track or target occupancy, instead following a throughput model.
• Doctors and nurses cost ratio declined to 26% — down ~1.8% QoQ on a 9% QoQ revenue increase against a largely fixed clinical and nursing cost base; CFO declined to guide a 26-27% run-rate, citing seasonality (Q2 higher-margin, Q3 slightly muted) and advised forecasting per industry trends rather than anchoring to the Q2 FY 2026-2027 base.

Losses Narrowing, But Break-Even Timeline Still Open

• Combined clinics + insurance loss narrowed from ~Rs.33 crore in Q1 FY 2026-2027 to Rs.20 crore in Q2 FY 2026-2027 — per Ravi Vishwanathan, countering the analyst's claim that losses keep rising; Cayman insurance losses fell from $3.5 million to $1.4 million (Q1 → Q2 FY 2026-2027).
• Q2 FY 2026-2027 segment split: ~Rs.23 crore total loss — ~Rs.14 crore from insurance and ~Rs.8 crore from clinics (per Group CFO); the analyst cited insurance loss narrowing from Rs.20 crore to Rs.14 crore and clinics from Rs.13 crore to ~Rs.7 crore.
• Analyst cited a combined ratio of 280% — vs 100-110% for established players (Q2 FY 2026-2027); Ravi Vishwanathan said ratios get distorted quarter-to-quarter, the claims ratio has come down significantly QoQ and top-line growth is substantial YoY, but it is too early to give a break-even timeline.
• Viren Shetty on commitment — "Neither we will give up on insurance, nor we will pursue this at any cost"; original strategies are being adapted while keeping spend low, with the aim to break even at a much smaller book than the peer set; he noted the IRDA chairman has made cutting insurance distribution costs a high priority.
• IRDAI's recent regulatory announcement — Ravi Vishwanathan said there is "no real change at the moment" to the insurance strategy; a decision on becoming an insurance distribution entity is "too soon to say" pending final guidelines.
• Reporting change — the clinic business will merge into the hospital segment going forward, with only the insurance loss reported separately (no specific effective FY stated).

Revenue Dip Masks Early Cost Synergies; ~Rs.1,700cr Net Debt

• UK carries ~Rs.1,700cr of net debt — (as of Q2 FY 2026-2027, per analyst Sajal Kapoor); UK EBITDA margin declined sequentially from ~8.8% to ~7% (Q2 vs Q1 FY 2026-2027, per analyst's figures).
• Margin decline attributed to separation-related costs — NH acquired only the hospitals division of a larger three-division group, requiring novation of all external vendor agreements (e.g., Microsoft), creating diseconomies of scale and vendor price increases; costs could not be quantified pre-acquisition but are now known and being actively mitigated.
• EBITDA benefits start with just 3-4 million of additional quarterly revenue — roughly the gap versus Q4 FY 2025-2026/Q1 FY 2026-2027 levels; cost initiatives only began flowing through one to two months before the call, and the Q2 FY 2026-2027 revenue decline means no cost-savings benefit is visible in earnings yet.
• NHS contracts reset once a year in March — with changes effective April 1, so any NHS-side change would only flow from the April 2027 reset (FY 2027-2028); NHS slowed contracting for all providers (industry-wide), which management framed as temporary given accumulating waiting lists.
• Non-NHS (private) share was ~7% of revenue at the start of UK operations — (period unspecified); management is seeing an increase in non-NHS business but is not yet disclosing the exact percentage change; it pushed back on the analyst's 1-2 year recovery frame but committed to no specific timeline.
• UK digital platform is ~4-5 months from full regulatory certification — (around Q4 FY 2026-2027), after which implementation of ATMA begins; the GCC for patient-facing communication was rolled out days before the call (late October 2026) and is working ahead of plan.
• CFO on cash conversion — UK cash conversion is not a problem as the NHS pays on time and partially in advance; the H1 FY 2026-2027 conversion slip (from a historical ~93% to ~88%, per the analyst) was attributed to collection delays in India and Cayman, expected to normalize with catch-up over the coming months/quarters of FY 2026-2027.

Cayman Margins >45% But Growth Ceiling Acknowledged

• Cayman hospital margins are north of 45% — (Q2 FY 2026-2027), a profile Anish Shetty said has held for several years, driven by the integrated care strategy and holistic system-cost reduction for hospitals, employers and insurers.
• Cayman insurance losses fell from 5.4mn (Q4 FY 2025-2026) to 3.7mn (Q1 FY 2026-2027) to 1.1mn in Q2 FY 2026-2027 — driven by repricing and purging of poor-performing accounts; management called the trajectory "better than plan" and is deliberately not focusing on insurance growth until losses are contained.
• Cayman reset calendar — the January 2027 price reset covers only a smaller cohort; the big reset is July 2027, from which point the company will exit most unprofitable books; management hopes losses will be negligible even before July 2027 but did not explicitly confirm the analyst's suggested H2 FY 2027-2028 break-even timeline.
• Management maintained the best days of Cayman growth are behind it — the small island's market size anchors growth; focus is on securing the existing patient base and a locked-in relationship "for many decades to come"; management declined to quantify a maximum revenue/run-rate for Cayman when asked by Shruti Mimani (Clearstone Family Office).
• International patients are ~6-7% of hospital revenue — (Q2 FY 2026-2027); growth is purely organic, mainly from Bangladesh on ~two-and-a-half decades of brand loyalty, plus non-Cayman Caribbean and some Latin American patients; NH is the only tertiary healthcare provider in the English-speaking Caribbean.
• Cayman ARPP grew 13% in Q2 FY 2026-2027 — but Anish Shetty cautioned that QoQ changes in ARPP, ARPOB or ALOS in Cayman are not informative due to heavy seasonal variation and a low volume base; investors should track discharge volumes, outpatient volumes and revenue over several quarters.

Integrated Care Across Geographies; ROCE Dilution to Bridge Over ~5 Years

• Group ROCE stands at 15 to 16% (FY 2026-2027) — reflecting recently completed large capex in Cayman, the UK investment, and India entering a capex phase; dilution coming purely from the UK is about 4 to 5% (FY 2026-2027), which management wants to bridge over the next 5 years or so.
• UK ROCE horizon — Group CFO Sandhya Jayaraman said a 5 to 7 year time horizon is appropriate for evaluating the UK business, as the company has just entered that market.
• AI strategy is "measured and grounded in practical application" — per Viren Shetty; AI in radiology predates LLMs and is a proven technology, while other use cases are limited to voice bots and simple data interpretations; error-prone AI in decision-making was characterized as a "tomorrow problem."
• End-state goal — NH is working to build a very large integrated healthcare system across at least two or three geographies (period unspecified), to reduce single-country currency/macro risk; management cited the UK and the Caribbean as markets where realization for the same work is much larger than in India.
• Operational synergies already enacted — a very large GCC for all international operations runs out of the Bangalore corporate office, with definite cost savings across hospitals in India, the UK, and Cayman; the CFO said no currency-specific factor needs to be built into forecasts on account of the GCC setup as it is still small.
• Cybersecurity flagged as a huge concern — Viren Shetty noted healthcare organizations have an especially large attack surface; a PHP vulnerability was patched very quickly in the recent period; the company needs to spend more money and build better systems, acknowledging some risk is beyond its control.

Bed Additions, ALOS Targets and Near-Term Watch Items

• Almost 635 beds planned for addition in FY 2027-2028 — but Group CFO Sandhya Jayaraman declined to guide on quarterly phasing; facility commissioning guidance will be shared one quarter in advance as facilities are readied for FY 2027-2028.
• ALOS target of 4-4.1 days over the next 4 to 6 quarters — Viren Shetty said management wants to bring ALOS down from the current 4.3-4.5 days (Q2 FY 2026-2027), extending into FY 2027-2028; the elevated ALOS was attributed to a higher mix of very high-ALOS procedures (transplants and bone marrow transplants) plus very high-acuity medical admissions.
• Oncology price cap goes live from 9 November 2026 (Q3 FY 2026-2027) — oncology is 15% of India hospital revenue (FY 2026-2027) and only a part of oncology drugs falls under the cap; better clarity thereafter; management supports transparent, affordable pricing and is not margin-focused.
• Eastern cluster porting issue — a change in the government in Bengal caused a porting issue under the existing scheme for certain categories of scheme patients; management expects this to settle in Q3 FY 2026-2027, with much stronger footfall growth foreseen for the eastern region in Q3 FY 2026-2027.
• Q3 and Q4 FY 2026-2027 outlook — after good IP and OP volume growth over Q1-Q2 FY 2026-2027, management foresees good footfalls in Q3 and Q4 FY 2026-2027, in addition to upcoming bed additions expected in two years' time (≈FY 2028-2029); smaller Karnataka units should see volumes pick up in coming quarters of FY 2026-2027 as payer mix is rationalized.
• Talent pipeline — close to 900 postgraduates in training across the network and more than 3,000 nursing students in training; the NAMA app and Atma technology have reduced nurses' non-clinical workload by more than 50-60%, which management said lowers burnout.